Skip to Main Content

Paper Details

CDP-ribitol prodrug treatment ameliorates ISPD-deficient muscular dystrophy mouse model.
Nature Communications
3
2022
CDP, CDP-ribitol, ISPD, ISPD-deficient muscular dystrophy, Ispd, Ribitol-phosphate, cardiomyopathy, central nervous system abnormalities, dystroglycan, dystrophic, fibroblasts, glycosylation defects, isoprenoid, isoprenoid synthase domain, mice, mouse, muscular dystrophy, patient, phosphate, ribitol, ribitol-phosphate, tetraacetylated CDP
Author NameAffiliation
Dirk J LefeberDonders Institute for Brain, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences
  • 1 - 1

Datasets

Release 1.2